"The U.S. Food and Drug Administration today approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis.
Psoriasis is a skin condition that causes patches of skin redness and irritation. Psoriasis is"...
Topically applied Taclonex® (calcipotriene and betamethasone dipropionate) Ointment can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS).
Taclonex® (calcipotriene and betamethasone dipropionate) Ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Taclonex® (calcipotriene and betamethasone dipropionate) Ointment is contraindicated in patients with erythrodermic, exfoliative and pustular psoriasis.
Last reviewed on RxList: 10/17/2007
This monograph has been modified to include the generic and brand name in many instances.
Additional Taclonex Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.